| Outcome Measures: |
Primary: Proximal tubular natriuresis, Measured by fractional excretion of sodium, up to 12 weeks | Secondary: Glomerular Filtration Rate, GFR, Glomerular Filtration Rate (GFR, based on plasma iohexol clearance) will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)|Systolic blood pressure, SBP, Systolic blood pressure (SBP) will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)|Body weight, Kilograms, Body weight will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)|Arterial stiffness, Measured using a Sphygmocor device, Arterial stiffness will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)|Systemic vascular resistance, Measured using non-invasive cardiac output monitor (NICOM), Systemic vascular resistance will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)|Urinary concentration of the renin-angiotensin aldosterone system (RAAS) markers, Measured using ELISA, Outcome will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)|Urinary EGF,FGF2,Eotaxin,TGFa,G-CSF,Flt-3L,GM-CSF,Fractalkine,IFNa2,IFNy,GRO,IL10,MCP-3,IL-12P40,MDC,IL-12P70,PDGF-AA,IL-13,PDGF-BB,IL-15,sCD40L,IL-17A,IL-1RA,IL1a,IL9,IL1B,IL2,IL3,IL4,IL5,IL6,IL7,IL8,IL10,MCP-1,MIP-1a,MIP-1B,RANTES,TNFalpha,TNFB,VEGF, 41-plex chemo/chemokine profile assay: urinary, Outcome will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)
|
